The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Subscribe To Our Newsletter & Stay Updated
